Systemic inflammation and the effects of short-term antibiotic treatment for PPM positive patients with stable COPD

Int J Chron Obstruct Pulmon Dis. 2019 Aug 23:14:1923-1932. doi: 10.2147/COPD.S217971. eCollection 2019.

Abstract

Objective: To evaluate patients with stable COPD for the presence of potentially pathogenic microorganisms (PPM), systemic inflammation and the effects of short-term antibiotic therapy in PPM positive patients.

Methods: From January 2016 to June 2017, we enrolled 96 stable COPD patients. Bacterial cultures from sputum collections were quantitated, along with markers for systemic inflammation including serum C-reactive protein (CRP), interleukin-8 (IL-8) and plasma fibrinogen (FIB) in all patients. All enrolled patients were followed for 12 months. Forty patients were identified as PPM positive and were randomly divided into an antibiotic group and a control group. The antibiotic group was treated with moxifloxacin orally for 6 days. Lung function and markers for systemic inflammation were repeatedly measured at 30 days and 6 months in PPM positive subjects.

Results: Binary logistic regression analysis showed that risk factors for PPM positive are bronchiectasis (OR 4.18, 95% CI 1.20-14.59; P=0.025), COPD assessment test (CAT) ≥20 (OR 17.55, 95% CI 2.82-109.18; P=0.002), spontaneous sputum (OR 15.09, 95% CI 1.36-168.02; P=0.027) and sputum purulence (OR 38.43, 95% CI 5.39-274.21; P=0.000). CRP and IL-8 were higher in PPM positive group than those in PPM negative group (P=0.001, P=0.007, respectively), but there were no differences of FIB between the two groups (P=0.086). Compared to the PPM negative group, the rate of acute exacerbation of COPD was higher (P=0.029) and time to next acute exacerbation was shorter (P=0.030) in PPM positive group. There were no differences in lung function and systemic inflammatory markers either in the control group or the antibiotic group at different time points of follow-up.

Conclusion: PPM exists in stable COPD patients and can cause systemic inflammation and is associated with acute exacerbation of COPD. Short-term antibiotic therapy had no effect on systemic inflammation nor on acute exacerbation of COPD.China Clinical Trials Registry: ChiCTR-IOR-15006769.

Keywords: C-reactive protein; COPD; antibiotics; interleukin-8; potentially pathogenic microorganisms; systemic inflammation.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Aged
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / adverse effects
  • Bacteria / drug effects*
  • Bacteria / isolation & purification
  • Bacterial Infections / diagnosis
  • Bacterial Infections / drug therapy*
  • Bacterial Infections / immunology
  • Bacterial Infections / microbiology
  • China
  • Disease Progression
  • Drug Administration Schedule
  • Female
  • Humans
  • Inflammation Mediators / analysis*
  • Male
  • Middle Aged
  • Moxifloxacin / administration & dosage*
  • Moxifloxacin / adverse effects
  • Pulmonary Disease, Chronic Obstructive / diagnosis
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / immunology
  • Pulmonary Disease, Chronic Obstructive / microbiology
  • Respiratory Tract Infections / diagnosis
  • Respiratory Tract Infections / drug therapy*
  • Respiratory Tract Infections / immunology
  • Respiratory Tract Infections / microbiology
  • Risk Factors
  • Sputum / immunology
  • Sputum / microbiology
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Inflammation Mediators
  • Moxifloxacin